Neo-adjuvant Androgen Deprivation Therapy, Pelvic Radiotherapy and RADium-223 for new presentation T1-4 N0/1 M1B adenocarcinoma of prostate (ADRRAD Trial)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Radium 223 chloride (Primary) ; Docetaxel; Goserelin; Leuprorelin; Leuprorelin; Triptorelin
Indications Adenocarcinoma; Prostate cancer
Focus Adverse reactions
Acronyms ADRRAD

29 Jun 2021 Results assessing safety and efficacy of combination of androgen deprivation therapy, up front docetaxel, radium-223 and external beam radiotherapy to prostate and pelvis in metastatic hormone sensitive prostate cancer, published in the Clinical Cancer Research.
15 Feb 2020 Results presented at the 2020 Genitourinary Cancers Symposium
13 Feb 2020 According to Bayers media release, data from this trial will be presented at the 2020 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15, 2020 in San Francisco, California.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com